Melanoma Clinical Trials

Birmingham :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Birmingham : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Birmingham : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Gilbert : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Scottsdale : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Scottsdale :

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Scottsdale : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

View More »

Scottsdale : Oncology Research Associates, Pllc D/B/A

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Scottsdale : Call for Information (Investigational Site 0004)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Scottsdale : Pinnacle Oncology Hematology

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Tucson : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Tucson : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Tucson : University of Arizona Cancer Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Tucson : Arizona Clinical Research

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Tucson : Call for Information (Investigational Site 0007)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Tucson :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Little Rock : University of Arkansas for Medical Sciences

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Rogers :

A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Beverly Hills : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Beverly Hills : Beverly Hills Cancer Center

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Beverly Hills : Call for Information (Investigational Site 0027)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Beverly Hills : Call for Information (Investigational Site 0061)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Duarte : City of Hope

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

View More »

Encinitas : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Encinitas : San Diego Pacific Oncology and Hematology Associates, Inc.

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Greenbrae :

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

La Jolla : Moores UCSD Cancer Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

La Jolla :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

La Jolla : Moores UCSD Cancer Center

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

La Jolla : Moores UCSD Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

La Jolla :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Los Angeles :

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

Los Angeles : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Los Angeles :

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Los Angeles :

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Los Angeles :

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Los Angeles :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Los Angeles :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Los Angeles :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Los Angeles : University Of California - Los Angeles

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Los Angeles : The Angeles Clinic & Research Institute

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Los Angeles :

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

Los Angeles : University of California Los Angeles

Combination of Temozolomide and Sunitinib in Treatment of Patients With Metastatic and Unresectable Malignant Melanoma

Los Angeles : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Los Angeles : Research Site Updated

Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

Los Angeles : Childrens Hospital Of La

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Los Angeles : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Los Angeles : USC Norris Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Los Angeles : University of California, Los Angeles

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Los Angeles : Jonsson Comprehensive Cancer Center

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Los Angeles : The Angeles Clinic and Research Institute

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Los Angeles : The Angeles Clinic and Research Institute

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Los Angeles : Call for Information (Investigational Site 0015)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Los Angeles : Call for Information (Investigational Site 0010)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Los Angeles : Call for Information (Investigational Site 0034)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Los Angeles : Call for Information (Investigational Site 0018)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Los Angeles :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Los Angeles : Cedars Sinai Medical Center

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Orange : Children'S Hospital Of Orange County

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Orange : Chao Family Comprehensive Cancer Center

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

Pleasant Hill :

A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Pleasant Hill : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

San Diego : UCSD Moores Cancer Center

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

San Francisco : University of San Francisco, California

A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases

San Francisco : St Mary's Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

San Francisco :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

San Francisco : San Francisco Oncology Associates

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

San Francisco : University of California, San Francisco

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

San Francisco : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

San Francisco : Research Site Updated

Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

San Francisco : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

San Francisco : Northern California Melanoma Center/ St. Mary's Medical Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

San Francisco : Call for Information (Investigational Site 0008)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

San Francisco : UCSF Helen Diller Comprehensive Cancer Center

Trial of pIL-12 Electroporation Malignant Melanoma

Santa Monica :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Santa Monica :

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

Santa Monica : The Angeles Clinic

Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

Santa Monica :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Santa Monica : John Wayne Cancer Institute

Trial of pIL-12 Electroporation Malignant Melanoma

Santa Rosa : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Stanford : Stanford Cancer Center - Stanford University

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Temecula : Pacific Dermatology Institute

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Vallejo : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Aurora :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Aurora : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Aurora : Children'S Hospital Colorado

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Aurora : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Aurora : University of Colorado Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

View More »

Aurora : Anschutz Cancer Pavilion

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Aurora : Call for Information (Investigational Site 0016)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Aurora :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Denver : University of Colorado, Denver

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

New Haven : Yale University School Of Medicine

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

New Haven : Yale University School Of Medicine

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

New Haven : Smilow Cancer Hospital at Yale New Haven

Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

New Haven : Yale School of Medicine

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

Washington : The Melanoma Center at the Washington Cancer Institute

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Washington : MedStar Clinical Research Ctr at Washington Hospital Center

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Washington : Call for Information (Investigational Site 0021)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Washington : Georgetown Lombardi Comprehsnive Cancer Center

The Effects of Vemurafenib on Immunity in Patients With Melanoma

Fort Lauderdale : Holy Cross Hospital

IMPULSE

View More »

Fort Lauderdale : Call for Information (Investigational Site 0017)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Fort Myers : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Fort Myers : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Fort Myers :

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Fort Myers :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Jacksonville : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Jacksonville : Baptist Cancer Institute

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Jacksonville : Call for Information (Investigational Site 0003)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Jacksonville : Baptist Cancer Institute

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Lakeland : Lakeland Regional Cancer Center

Trial of pIL-12 Electroporation Malignant Melanoma

Miami :

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

Miami Beach : Research Site

A Phase 1 Study to Evaluate MEDI4736

Miami Beach : Mount Sinai Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Miami Beach : Mount Sinai Medical Center

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Miami Beach : MSMC Research Program

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Miami Beach : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Miami Beach : Mount Sinai Medical Center Comprehensive Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Miami Beach : Mount Sinai Medical Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Miami Beach : Call for Information (Investigational Site 0053)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Orlando : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Orlando : Md Anderson Cancer Center Orlando

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Orlando : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Orlando : Md Anderson Cancer Center Orlando

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Orlando : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Orlando : MD Anderson Cancer Center-Orlando

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Ormond Beach : Ameriderm Research

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

St. Petersburg :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

St. Petersburg :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Tallahassee : Dermatology Associates of Tallahassee Updated

Post-Approval Study of MelaFind

Tampa : Research Site

A Phase 1 Study to Evaluate MEDI4736

Tampa :

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

Tampa : oH. Lee Moffitt Cancer Center/University of South Florida Moffitt SC

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Tampa : H. Lee Moffitt Cancer Center/University of South Florida Moffitt 5

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Tampa : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Tampa : H. Lee Moffitt Cancer Center & Research Institute

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Tampa : H. Lee Moffitt Cancer Center & Research Institute

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC

Tampa : H. Lee Moffitt Cancer Center & Research Inst, Inc

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Tampa : Call for Information (Investigational Site 0018)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Tampa : H. Lee Moffitt Cancer Center & Research Institute

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)

Tampa : H. Lee Moffitt Cancer Center

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma

Tampa :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

West Palm Beach : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Savannah : Memorial University Medical Center

CTSU/ECOG E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High-Risk Melanoma

View More »

Atlanta : Taofeek Owonikoko, MD, PhD

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Atlanta : Winship Cancer Institute

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Atlanta : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Atlanta : Emory University School of Medicine

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Atlanta : Winship Cancer Institute

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Augusta : Research Site

A Phase 1 Study to Evaluate MEDI4736

Elgin : Sherman Health

ECOG E1609 Phase III Randomized Study of Adjuvant Ipilimumab Versus High-Dose Recombinant Interferon Alfa-2b in Patients With High-Risk Stage IIIB, IIIC, or IV Melanoma

View More »

Chicago : Rush University Medical Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Chicago :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Chicago : Rush University Medical Center

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Chicago : Research Site Updated

Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

Chicago : University Of Chicago

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Chicago : Rush Pres St Lukes Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Chicago : Robert H. Lurie Comprehensive Cancer Center, Northwestern University

Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

Chicago : University of Chicago

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Maywood : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Maywood : Loyola University Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Niles : Oncology Specialists, SC

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Niles : Oncology Specialists, SC (OSSC)

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Park Ridge :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Park Ridge : Oncology Specialists, SC

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Park Ridge :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Goshen :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Goshen : Indiana University Health Goshen Center for Cancer Care

Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

Indianapolis : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Indianapolis : Investigative Clinical Research of Indiana

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Indianapolis :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

View More »

Indianapolis :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Indianapolis : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Indianapolis : Indiana University Melvin and Bren Simon Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Indianapolis : Indiana University - Simon Cancer Center

Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

Indianapolis : Indiana University Melvin And Bren Simon Cancer Center

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Indianapolis : Investigative Clinical Research of Indiana

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Iowa City : University of Iowa Hospitals and Clinics

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Iowa City : Research Site Updated

Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

Iowa City : University of Iowa Hospitals and Clinics

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Iowa City : University of Iowa Hospitals and Clinics

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Iowa City : Call for Information (Investigational Site 0028)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

View More »

Iowa City : University of Iowa Hospitals and Clinics Updated

Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat

Lexington : Central Kentucky Research Associates

Melanoma Vaccine

View More »

Lexington : Central Kentucky Research Associates

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Lexington : Central Baptist Hospital

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Louisville :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Louisville : James Graham Brown Cancer Center

Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

Louisville : University Of Louisville Medical Center, Inc., Dba

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Louisville : University of Louisville Hospital

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Baton Rouge : The Baton Rouge Clinic, AMC

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Baltimore : The Johns Hopkins University Updated

Post-Approval Study of MelaFind

Baltimore : Weinberg Cancer Institution at Franklin Square

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Baltimore : Call for Information (Investigational Site 0031)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Bethesda :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Lutherville : Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Boston : Massachusetts General Hospital Mass General 2

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Boston : Dana Farber Cancer Institute DFCI (4)

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Boston : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Boston : Massachusetts General Hospital Mass General 2

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Boston :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

View More »

Boston : Dana Farber Cancer Institute

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Boston : Massachusetts General Hospital

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Boston : Beth Israel Deaconess Medical Center

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Boston : Dana Farber Cancer Institute

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Boston : Dana-Farber Cancer Institute

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Boston : Dana-Farber Cancer Institute

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Boston : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Boston : Beth Israel Deaconess Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Boston : Massachusetts Eye & Ear Infirmary

Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Boston : Dana Farber Cancer Institute DFCI - Brookline

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

Boston : Dana-Farber Cancer Institute

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Boston : Massachusetts General Hospital

STA-9090(Ganetespib) in Metastatic Ocular Melanoma

Boston : Dana-Farber Cancer Institute

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

Boston : Call for Information (Investigational Site 0011)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Boston : Dana Farber Cancer Institute

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)

Boston : Dana-Farber Cancer Institute

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)

Boston : Beth Israel Deaconess Medical Center

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Boston : Massachusetts General Hospital

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Boston : Dana-Farber Cancer Institute

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Boston : Massachusetts General Hospital

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Rockland : Please contact the US Medical Information in

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Ann Arbor : University Of Michigan Health System

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Ann Arbor : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Detroit :

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Detroit : Wayne State University/Karmanos Cancer Institute Wayne St

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Detroit :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

View More »

Detroit :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Detroit : Karmanos Cancer Institute

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Detroit : Karmanos Cancer Institute

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Detroit : Karmanos Cancer Institute

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Detroit : Barbara Ann Karmanos Cancer Institute

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Detroit : Henry Ford Medical Center

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Fridley : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Minneapolis : University of Minnesota Masonic Cancer Center

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Minneapolis : University of Minnesota Masonic Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Minneapolis : University of Minnesota Masonic Cancer Institute

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Rochester : Mayo Clinic

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

View More »

Rochester : Mayo Clinic Cancer Center, Mayo Clinic Rochester

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Rochester : Call for Information (Investigational Site 0002)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Kansas City : Center for Pharmaceutical Research

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Springfield : Mercy Medical Research Institute

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

St. Louis : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

St. Louis :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

St. Louis : Washington University School Of Medicine

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

View More »

St. Louis : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

St. Louis : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

St. Louis : Washington University in St. Louis

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

St. Louis : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

St. Louis : Washington University in St. Louis

Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

St. Louis : Washington University School of Medicine

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

St. Louis : St. Louis Hospital

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

St. Louis :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

St. Louis : Washington University in St. Louis

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Lincoln : Southeast Nebraska Hematology & Oncology Consultants, Lincol

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Omaha : Midwest Cancer Center - Legacy

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Henderson : Comprehensive Cancer Center Of Nevada

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Las Vegas : Comprehensive Cancer Centers of Nevada

Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers

Las Vegas : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Lebanon : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Lebanon : Dartmouth-Hitchcock Medical Center

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Lebanon : Dartmouth Hitchcock Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Lebanon : Norris Cotton Cancer Center / Dartmouth-Hitchcock Medical Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Lebanon : Dartmouth-Hitchcock Medical Center

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Hackensack : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Hackensack : John Theurer Cancer Center at Hackensack University Medical Center

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Hackensack : John Theurer Cancer Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Hackensack : Call for Information (Investigational Site 0032)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Morristown : Atlantic Melanoma Center

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

View More »

Morristown : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Morristown : Atlantic Melanoma Center

Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

New Brunswick : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

New Brunswick : Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

Effects of Monoclonal Antibody GC1008 in Blood Samples From Patients With Unresectable Locally Advanced or Metastatic Kidney Cancer or Malignant Melanoma Treated on Clinical Trial NCI-06-C-0200

New Brunswick : Cancer Center of NJ

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Randolph :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Albuquerque : New Mexico Cancer Care Alliance

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Bronx : Saint Luke's-Roosevelt Hospital Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Bronx : Montefiore Medical Center

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Buffalo : Roswell Park Cancer Institute

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

New York : Research Site

A Phase 1 Study to Evaluate MEDI4736

New York : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

View More »

New York :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

New York :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

New York :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

New York : Memorial Sloan Kettering Cancer Center

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

New York : Nyu Clinical Cancer Center

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

New York : Memorial Sloan Kettering Cancer Center

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

New York : Memorial Sloan Kettering Cancer Center

Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation

New York : New York University Langone Clinical Cancer Center

CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

New York : Memorial Sloan Kettering Cancer Center

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

New York : Research Site Updated

Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

New York : Memorial Sloan Kettering Cancer Ctr

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

New York : Memorial Sloan Kettering Cancer Center

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

New York : Mount Sinai School Of Medicine

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

New York : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

New York : Memorial Sloan-Kettering Cancer Center

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

New York : Memorial Sloan Kettering Cancer Center MSKCC 4

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

New York : Mount Sinai School of Medicine

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

New York : New York University

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

New York :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

New York : Memorial Sloan Kettering Cancer Center

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

New York : Melanoma and Sarcoma Service / Memorial Sloan Kettering Cancer Center

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

Raleigh : Wake Research Associates

Melanoma Vaccine

View More »

Chapel Hill : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Chapel Hill : Research Site Updated

Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

Chapel Hill : Lineberger Comprehensive Cancer Center, University of North Carolina Updated

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Chapel Hill : Call for Information (Investigational Site 0029)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Charlotte : Levine Cancer Institute

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Charlotte : Levine Cancer Institute

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Charlotte : Blumenthal Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Durham : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Durham :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Durham : Duke University Medical Center

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Durham : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Durham : Duke University Hospital

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Durham : Duke University Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Durham : Call for Information (Investigational Site 0036)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Huntersville :

A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma

Raleigh : Wake Research Associates

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Winston-Salem : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Winston-Salem : Wake Forest University Baptist Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Winston-Salem : Wake Forest University School of Medicine, Comprehensive Cancer Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Canton : Gabrail Cancer Center Research

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Cincinnati : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Cincinnati : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Cleveland : University Hospitals Of Cleveland

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Cleveland : Case Comprehensive Cancer Center

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

View More »

Cleveland : University Hospitals Of Cleveland

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Cleveland : University Hospitals Siedman Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Columbus : The Ohio State University Comprehensive Cancer Center

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Columbus : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Columbus : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Bend : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Portland : Oregon Health & Science University OHSU 2

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Portland : Providence Oncology And Hematology

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Portland : Providence Cancer Center

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

Portland : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Portland : Providence Cancer Center

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Portland : Providence Portland Medical Center

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Portland : Providence Portland Medical Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Portland : Portland Providence Medical Center

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Portland : Kaiser Permanente Northwest

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Portland : Oregon Health and Science University

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Allentown : Lehigh Valley Health Network

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)

Allentown : Lehigh Valley Hospital

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Bethlehem : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Bethlehem :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Bethlehem : Saint Luke's Hospital and Health Network

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

View More »

Bethlehem : Call for Information (Investigational Site 0001)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Easton : St.Luke'S Cancer Center

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Easton : St. Luke's Hospital, Anderson Campus

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Philadelphia :

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

Philadelphia : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Philadelphia : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Philadelphia :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Philadelphia : Thomas Jefferson University

Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases

Philadelphia : Thomas Jefferson University

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

Philadelphia : Kimmel Cancer Center at Thomas Jefferson Univ.

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Philadelphia : Call for Information (Investigational Site 0016)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Philadelphia : Call for Information (Investigational Site 0038)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Philadelphia : Call for Information (Investigational Site 0012)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Philadelphia : Fox Chase Cancer Center

Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma

Philadelphia : University Of Pennsylvania

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)

Philadelphia : University of Pennsylvania

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Pittsburgh : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Pittsburgh : Upmc Cancer Pavilion

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Pittsburgh : UPMC Cancer Centers

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Pittsburgh : Hillman Cancer Center Updated

Melanoma Molecular Profiling Analysis

Pittsburgh : UPMC Hillman Cancer Center Updated

Pilot Study of IFN α2b for Melanoma Patients

Pittsburgh : Hillman Cancer Research Pavilion, Div. of Medical Oncology

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Pittsburgh : University of Pittsburgh

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Pittsburgh : Call for Information (Investigational Site 0013)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Pittsburgh : University of Pittsburgh Cancer Institute

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Pittsburgh :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Greenville : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Memphis : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Memphis :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Memphis : St. Jude Children'S Research Hospital

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Nashville : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Nashville : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

View More »

Nashville :

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

Nashville : Sarah Cannon Research Institute

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Nashville :

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Nashville :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Nashville :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Nashville : Vanderbilt Univeresity Medical Center

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Nashville : Tennessee Oncology, Pllc

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Nashville :

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

Nashville : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Nashville : Research Site Updated

Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

Nashville : Vanderbilt-Ingram Cancer Ctr

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

Nashville : GSK Investigational Site

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Nashville : Call for Information (Investigational Site 0033)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Nashville : Vanderbilt-Ingram Cancer Center

Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Nashville :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Nashville : Vanderbilt University

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Nashville : Sarah Cannon Research Institute

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Dallas : Research Across America

Do You Have Melanoma?

View More »

Amarillo : Don and Sybil Harrington Cancer Center

Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Dallas : Mary Crowley Cancer Research Centers - Medical City

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Dallas : Mary Crowley Cancer Research Centers

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Dallas : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Dallas : Mary Crowley Cancer Research Centers

Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer

Dallas : Mary Crowley Cancer Research Centers

Phase II FANG in Advanced Melanoma

Dallas : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Dallas : Mary Crowley Cancer Research Center

Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

Dallas : Dallas Surgical Group

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Dallas : Research Across America

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Dallas : Mary Crowley Cancer Research Center

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Dallas :

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

Dallas : Mary Crowley Cancer Research Center

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Dallas : Mary Crowley Cancer Research Centers

Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer

Houston : UT MD Anderson Cancer Center Updated

A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma

Houston : MD Anderson Cancer Center/University of Texas MD Anderson 2

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Houston :

A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma

Houston :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Houston :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Houston : UT MD Andreson Cancer Center

GSK2118436 and GSK1120212

Houston : UT MD Anderson Cancer Center Updated

High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Houston : UT MD Anderson Cancer Center

Ipilimumab for Uveal Melanoma

Houston : UT MD Anderson Cancer Center

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Houston : The University of Texas MD Anderson Cancer Center

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization

Houston : The University Of Texas Md Anderson Cancer Center

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Houston : University of Texas MD Anderson Cancer Center

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Houston : MD Anderson Cancer Center

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Houston : University of Texas M.D. Anderson Cancer Center

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Houston : University of Texas MD Anderson Cancer Center

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Houston : Md Anderson Can Cnt

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Houston : Call for Information (Investigational Site 0012)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Houston : Call for Information (Investigational Site 0060)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Houston : UT MD Anderson Cancer Center

Study of Weekly LOC-paclitaxel Injection for Melanoma

Houston : The University of Texas MD Anderson Cancer Center

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

Houston : UT MD Anderson Cancer Center

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

San Antonio :

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

San Antonio : Call for Information (Investigational Site 0001)

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

San Antonio : The START Center

Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma

San Antonio : Cancer Therapy and Research Center

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Murray : Intermountain Medical Center

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Salt Lake City : Huntsman Cancer Institute

A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma

Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Salt Lake City : Huntsman Cancer Institute

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Salt Lake City : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Salt Lake City : Huntsman Cancer Institute

Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks

Salt Lake City : Research Site Updated

Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma

Salt Lake City : Primary Children's Medical Center

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Salt Lake City : The Huntsman Cancer Institute, University of Utah

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Salt Lake City : Huntsman Cancer Institute

Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Burlington : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Burlington : Fletcher Allen Health Care, Inc.

Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma

Charlottesville : University of Virginia

A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients

Charlottesville : University of Virginia Health System

A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Charlottesville : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Charlottesville : University Of Virginia Health System

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Charlottesville : University of Virginia Hospital

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

View More »

Charlottesville : University of Virginia

Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

Norfolk : Clinical Research Associates of Tidewater

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients

Seattle : Seattle Cancer Care Alliance

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

Seattle : Seattle Cancer Care Alliance

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Seattle : Call for Information (Investigational Site 0025)

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Seattle : Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Trial of pIL-12 Electroporation Malignant Melanoma

Morgantown : West Virginia University - Clinical Trials Research Unit

ECOG 1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma

Morgantown : West Virginia University - Clinical Trials Research Unit

N0879: A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma

Madison : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Milwaukee : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Buenos Aires : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Buenos Aires : Instituto Médico Alexander Fleming

Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients

Caba : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Capital Federal : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Capital Federal : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Rosario : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

San Miguel de Tucumán : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Santa Fe : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Viedma : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Adelaide : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Adelaide : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Adelaide, SA : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Albury/Wodonga : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Ashford SA : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

View More »

Auchenflower : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Box Hill : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Camperdown : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Camperdown : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Casuarina : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

East Melbourne : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

East Melbourne :

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Frankston : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Gateshead : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Greenslopes : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Greenslopes : GSK Investigational Site

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.

Greenslopes : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Greenslopes : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Greenslopes Qld : Local Institution

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma

Heidelberg : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Heidelberg : Austin Health, LICR Melbourne Austin Branch

A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma

Heidelberg : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Herston : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Herston :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Herston : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Herston : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Hobart : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Launceston : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Lismore : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Malvern : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Melbourne : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Melbourne :

A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Melbourne : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Nedlands : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Nedlands : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

North Ryde : Merck Sharp & Dohme

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

North Ryde : Merck Sharp & Dohme

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

North Sydney : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

North Sydney : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

North Sydney : GSK Investigational Site

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.

North Sydney : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

North Sydney : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

North Sydney : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Parkville : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Perth : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Perth :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Prahan : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Prahran : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

South Brisbane : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Southport : Local Institution

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma

Townsville :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Wendouree : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Westmead : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Westmead :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Westmead : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Westmead : Local Institution

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Westmead : Local Institution

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma

Wodonga : Updated

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Woodville :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Woodville : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Woodville South : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Woolloongabba : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Woolloongabba : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Woolloongabba : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Woolloongabba : Research site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Graz : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Innsbruck :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Innsbruck : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Linz : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Linz : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

View More »

Salzburg : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Salzburg : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Salzburg : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

St. Pölten : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Vienna : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Wels : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Wels :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Wien : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Wien : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Wien : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Antwerp : Universitair Ziekenhuis Antwerpen

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Brasschaat : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Brussel : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Brussels : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Brussels : Jules Bordet Institute

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

View More »

Brussels : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Brussels : Cliniques universitaires Saint-Luc, Centre du Cancer

Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients

Bruxelles : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Bruxelles : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Bruxelles :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Bruxelles : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Edegem : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Edegem : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Edegem : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Gent :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Gent : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Gent : Local Institution

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

Hasselt : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Hasselt :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Jette : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Jette : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Kortrijk : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Kortrijk :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Kortrijk : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Leuven : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Leuven : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Leuven : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Leuven : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Liège : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Namur : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Roeselare : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Wilrijk : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Belo Horizonte : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Ijui : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Itajaí : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Porto Alegre : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Rio de Janeiro : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

View More »

Salvador : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

São Paulo : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

São Paulo - SP : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Calgary : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Edmonton : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Edmonton : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Edmonton : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Halifax : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Hamilton : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Hamilton : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Kingston : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Kirkland : Merck Frosst Canada

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Moncton : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Montreal : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Montreal : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Montreal : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Montreal :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Montreal : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Montreal : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Oshawa : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Ottawa :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Ottawa : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Quebec : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Quebec :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Quebec : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Sainte-foy : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Toronto : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Toronto : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Toronto : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Toronto : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Toronto :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Toronto : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Vancouver :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Vancouver : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Windsor : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Winnipeg :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Winnipeg : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Brno : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Hradec Kralove : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Hradec Kralove :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Olomouc : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Olomouc : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Ostrava - Poruba : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Ostrava - Poruba :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Pardubice : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Prague : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Praha : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Praha :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Praha 10 : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Praha 2 : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Zlin : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Aarhus : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Århus C : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Herlev : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Herlev : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Odense : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

View More »

Odense : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Guayaquil :

A Study of RO5185426 in Patients With Metastatic Melanoma

Portoviejo :

A Study of RO5185426 in Patients With Metastatic Melanoma

Tallinn :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Tartu :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Helsinki : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Jyvaskyla : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Tampere : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Turku : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Avignon Cedex 2 : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Bayonne : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Bordeaux : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Bordeaux : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Bordeaux :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

View More »

Bordeaux : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Bordeaux : Hôpital Saint-André

DNA Repair Inhibitor & Irradiation on Melanoma

Bordeaux : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Bordeaux : Local Institution

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma

Bordeaux : Local Institution

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Boulogne sur Mer : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Boulogne-Billancourt : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Boulogne-Billancourt : Hôpital Ambroise Paré

DNA Repair Inhibitor & Irradiation on Melanoma

Brest : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Brest Cedex : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Dijon : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Dijon : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Grenoble : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Grenoble : Local Institution

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma

Lille : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Lille : Centre Oscar Lambret

DNA Repair Inhibitor & Irradiation on Melanoma

Lille : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Lille : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Lille : Local Institution

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma

Lyon : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Lyon Cedex 08 : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Marseille : Hôpital Sainte Marguerite

A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit

Marseille : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Marseille : Hôpital de la Timone

DNA Repair Inhibitor & Irradiation on Melanoma

Marseille : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Marseille cedex 5 : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Marseille cedex 5 : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Marseille Cedex 5 : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Montauban : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Montivilliers : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Montpellier : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Montpellier : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Montpellier : Local Institution

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma

Montpellier cedex 5 : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Nantes : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Nantes : Hôpital hôtel-Dieu

DNA Repair Inhibitor & Irradiation on Melanoma

Nantes : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Nantes : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Nantes : Centre Hospitalier Universitaire de Nantes

Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face

Nantes Cedex 1 : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Nice : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Paris : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Paris : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Paris : Groupe Hospitalier Cochin - Hôtel Dieu-Broca

DNA Repair Inhibitor & Irradiation on Melanoma

Paris : Institut Curie

DNA Repair Inhibitor & Irradiation on Melanoma

Paris : Hôpital Saint-Louis

DNA Repair Inhibitor & Irradiation on Melanoma

Paris : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Paris : Local Institution

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma

Paris : MSD France

Study of MK-3475 (Lambrolizumab) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM7)

Paris : Local Institution

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Paris Cedex 10 : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Paris Cedex 10 : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Paris cedex 18 : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Pierre Benite : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Pierre Benite : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Pierre Benite : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Quimper : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Reims Cedex : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Rennes : Rennes University Hospital

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

Rennes : Centre Eugène Marquis

cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

Rennes : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Rennes Cedex : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Toulouse : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Toulouse Cedex : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Toulouse Cedex 3 : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Toulouse Cedex 3 : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Vandoeuvre les Nancy : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Villejuif : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Villejuif : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Villejuif : Local Institution

Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma

Villejuif Cedex : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Villejuif cedex : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Aachen : Dept of Dermatology, University of Aachen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Augsburg : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Augsburg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Augsburg : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Berlin : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

View More »

Berlin : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Berlin : Dept of Dermatology, University of Berlin Charite

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Berlin : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Bochum : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Bochum : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Bochum : Dept of Dermatology, University of Bochum

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Bonn : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Bonn : Medizinisches Zentrum Bonn Friedensplatz

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Bonn : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Bonn : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Buxtehude : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Buxtehude : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Buxtehude : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Buxtehude : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Buxtehude : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Chemnitz : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Dresden : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Düsseldorf : Research site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Erfurt : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Erfurt : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Erfurt : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Erfurt : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Erfurt : Local Institution

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Erlangen : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Erlangen : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Essen : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Essen : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Essen : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Essen : GSK Investigational Site

A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.

Essen : Dept of Dermatology, University of Essen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Essen : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Essen : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Essen : Medizinische Fakultät der Universität Duisburg-Essen

RBL001/RBL002 Phase I Clinical Trial

Frankfurt : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Frankfurt / Main : Dept of Dermatology, University of Frankfurt

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Frankfurt am Main : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Frankfurt/Oder : Dermatology, Klinikum Frankfurt/Oder

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Freiburg : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Freiburg : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Freiburg : University Medical Center Freiburg, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Gera : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Gera : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Gera : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Goettingen : Local Institution

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Haar : Merck Sharp & Dohme GmbH

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Hamburg : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Hannover : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Hannover : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Hannover : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Hannover : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Hannover : Dept of Dermatology, University of Hannover

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Hannover : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Hannover : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Hannover : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Heidelberg : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Heidelberg : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Heidelberg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Heidelberg : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Heidelberg : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Heilbronn : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Homburg/Saar : Dept of Dermatology, Saarland University

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Jena : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Jena :

A Study of RO5185426 in Patients With Metastatic Melanoma

Jena : Dept of Dermatology, University of Jena

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Kiel : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Kiel : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Kiel : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Kiel :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Kiel : Dept of Dermatology, University of Schleswig-Holstein Campus Kiel

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Kiel : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Kiel : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Kiel : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Koeln : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Koeln : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Koeln :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Koeln : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Koeln : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Koln : Local Institution

Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Köln : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Köln : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Köln : University Medical Center Collogne, Department of Dermatology

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Leipzig : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Leipzig : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Leipzig : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Lübeck : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Ludwigshafen : Dermatology, Klinikum Ludwishafen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Ludwigshafen : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Luebeck : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Luebeck : Dept of Dermatology, University of Schleswig-Holstein Campus Luebeck

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Luebeck : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Magdeburg : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Magdeburg : Dept of Dermatology, Univeristy of Magdeburg

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Magdeburg : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Magdeburg : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Mainz : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Mainz : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Mainz :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Mainz : Dept of Dermatology, University of Mainz

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Mainz : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Mainz : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Mainz : Universtitätsmedizin der Johannes-Gutenberg Universtität

RBL001/RBL002 Phase I Clinical Trial

Manheim : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Mannheim : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Mannheim : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Mannheim :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Mannheim : Dept of Dermatology, University of Mannheim

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Mannheim : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Mannheim : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Marburg : Dept of Dermatology, University of Marburg

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Muenchen : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Muenchen : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Muenchen : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Muenchen : Dept of Dermatology, University of Muenchen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Muenchen : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Muenster : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Muenster :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Muenster : Dept of Medical Oncology, Fachklinik Hornheide

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Muenster : Dept of Dermatology, University of Muenster

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

München : Research site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Munich : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Münster : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Nuernberg : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Nuernberg : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Plauen : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Quedlinburg : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Quedlinburg : Dermatology, Klinikum Dorothea Christiane Erxleben

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Regensburg : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Regensburg : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Regensburg : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Regensburg : University of Regensburg

Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma

Tübingen : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Tübingen : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Tübingen : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Tuebingen : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Tuebingen :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Tuebingen : Dept of Dermatology, University of Tuebingen

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Tuebingen : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Tuebingen : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Ulm : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Wiesbaden :

A Study of RO5185426 in Patients With Metastatic Melanoma

Wuerzburg : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Wuerzburg : Dept of Dermatology, University of Wuerzburg

Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC

Wuerzburg : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Wuerzburg : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Würzburg : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Athens : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

N. Faliro : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Thessaloniki : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Budapest : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Budapest : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Debrecen : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Gyula : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Kaposvár : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Miskolc : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Szeged : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Szeged : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Co.Cork : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Cork : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Dublin : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Dublin : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Galway : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Tullamore : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Beer Sheva : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Haifa : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Jerusalem : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Jerusalem : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Jerusalem : Oncology institute, Shaare Zedek Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

View More »

Jerusalem : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Ramat Gan : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Ramat-Gan : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Tel Aviv : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Tel Hashomer : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel Hashomer : Oncology Institute, Sheba Medical Center

IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma

Tel-Aviv : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Bari : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Bari :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Bari : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Bergamo : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Bergamo :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

View More »

Bergamo : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Brescia : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Candiolo (TO) : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Genova : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Genova : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Genova : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Genova :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Genova :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Genova : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Genova : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Genova : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Meldola - FC : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Milano : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Milano :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Milano :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Milano : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Milano : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Milano : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Milano : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Napoli : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Napoli : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Napoli : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Napoli :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Napoli : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Napoli : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Napoli : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Padova : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Padova : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Padova : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Padova : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Padova : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Pisa : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Roma : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Roma : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Roma :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Roma :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Roma : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Roma : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Siena : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Siena :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Siena : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Siena : GSK Investigational Site

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Siena : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Chiyoda-Ku, Tokyo : MSD K.K.

A Study of Pegylated Interferon Alfa-2b as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (P08556)

Chuo-ku : Local Institution

Phase 2 Study of Ipilimumab Plus DTIC in Japanese Advanced Melanoma Patients

Goyang-si, Gyeonggi-Do : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Seoul : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Amsterdam : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Amsterdam : Antoni van Leeuwenhoek Ziekenhuis

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Amsterdam : Vrije Universiteit medisch centrum (Vumc)

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Amsterdam : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Amsterdam : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

View More »

Groningen : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Groningen : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Groningen : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Haarlem : Merck Sharp & Dohme BV

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Leeuwarden : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Leiden : Leids Universitair Medisch Centrum (LUMC)

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Leiden : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Leiden : Novartis Investigative Site

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Maastricht : Novartis Investigative Site

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

Maastricht : Maastricht Universitair Medisch Centrum

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Maastricht : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Rotterdam : Novartis Investigative Site

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Rotterdam : Erasmus MC

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Rotterdam : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Rotterdam : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Rotterdam : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Utrecht : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Zwolle : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Auckland : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Auckland : Updated

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Christchurch : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Christchurch : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Hamilton : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

View More »

Hamilton : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Newtown, Wellington : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Palmerston North : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Tauranga : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Drammen : MSD Norge A/S

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Kristiansand : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Oslo : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Oslo : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Oslo : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Stavanger : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Gdansk : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Konin : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Poznan : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Poznan : WCO (Great Poland Cancer Centre)

Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma

Warszawa : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Timisoara :

A Study of RO5185426 in Patients With Metastatic Melanoma

Chelyabinsk : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Kazan : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Krasnodar :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Magnitogorsk : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Moscow : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

View More »

Moscow :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Moscow :

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

Moscow : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Nizhniy Novgorod : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Ryazan : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

St. Petersburg : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

St. Petersburg : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Stavropol : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Durban : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Johannesburg : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Pietermaritzburg : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Pretoria : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Badalona : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Barcelona : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Barcelona : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Barcelona : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Barcelona : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

View More »

Barcelona : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Barcelona : Novartis Investigative Site

A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Barcelona :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Barcelona : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Barcelona : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Barcelona : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Hospitalet de Llobregat, Barcelona : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Las Palmas De Gran Canaria : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

l'Hospitalet de Llobregat : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Madrid : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Madrid : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Madrid : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Madrid : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Madrid : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Madrid : Merck Sharp and Dohme de Espana S.A.

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Majadahonda : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Málaga : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Marbella :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Palma de Mallorca : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Pamplona : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Pamplona : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Pamplona : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Pamplona : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Pamplona : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Santiago de Compostela : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Sevilla : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Seville : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Valencia : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Valencia : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Valencia : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Valencia : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Goteborg : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Göteborg : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Göteborg : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Göteborg : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Jönköping : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

View More »

Jönköping :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Linköping : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Lund : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Lund : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Lund : Lunds Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Malmö : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Sollentuna : MSD

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Stockholm : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Stockholm : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Stockholm : Södersjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Stockholm : Karolinska Sjukhuset

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Umeå : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Umeå : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Umeå : Norrlands Universitetssjukhus

SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma

Uppsala : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Uppsala : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Uppsala : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Växjö :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Baden : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Basel : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Basel : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Chur : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Genève : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

View More »

Lausanne : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Lausanne : Oncology Department, CHUV

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients

Lucerne 6 : MSD International GmbH

Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)

Lugano : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Zuerich : Novartis Investigative Site

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Zuerich : Novartis Investigative Site

Dose Escalation Study to Investigate Safety, PK and Anti-tumor Activity of Pasireotide in Patients With Metastatic Melanoma or Merkel Cell Carcinoma

Zürich : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Zürich : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Zürich : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Zürich : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Tainan : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Taipei : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Taoyuan : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Bangkok : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Songkla : Novartis Investigative Site

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Adana :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Adana :

A Study of RO5185426 in Patients With Metastatic Melanoma

Ankara :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Ba?kesir :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Bursa :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

View More »

Diyarbakir :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Edirne :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Erzurum :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Gaziantep :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Isparta :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Istanbul :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Izmir :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Kayseri :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Konya :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Malatya :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

S?hhiye, ANKARA :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Tokat :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Trabzon :

A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics

Dnipropetrovsk : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Dnipropetrovsk : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Donetsk : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Donetsk : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Kharkiv : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

View More »

Khmelnytskyi : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Kyiv : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Kyiv : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Lviv : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Lviv : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Sumy : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Sumy : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Uzhgorod : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Bebington : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Birmingham : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Birmingham : Queen Elizabeth Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Cambridge : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Cambridge : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

View More »

Cambridge : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Cambridge : Cambridge University Hospitals NHS Foundation Trust

HYPAZ: Hypertension Induced by Pazopanib

Cambridge : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Cambridge : Addenbrooke's Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Chelmsford : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Edgbaston, Birmingham : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Edinburgh : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Edinburgh :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Glasgow : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Glasgow : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Glasgow : The Beatson Institute

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Leeds : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Leeds : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Leeds : St James' Institute of Oncology

Study of a DNA Immunotherapy to Treat Melanoma

Leeds : St James Hospital

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Leicester : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

London : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

London : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

London : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

London : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

London : King's College London Guy's Hospital Campus

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

London : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

London : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

London : Novartis Investigative Site

Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients

Manchester : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Manchester : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Manchester : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Manchester : Christie Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Newcastle upon Tyne : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Newcastle upon Tyne : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Newcastle Upon Tyne :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Newcastle upon Tyne : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Newcastle Upon Tyne and Wear : Newcastle Upon Tyne NHS Foundation Trust

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Northwood : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Nottingham : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Nottingham : Department of Clinical Oncology, City Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Oxford : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Oxford :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Oxford : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Oxford : NIHR Biomedical Research Centre

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Oxfordshire : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Preston : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Preston : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Southampton : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Southampton : Local Institution

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Southampton : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Southampton : GSK Investigational Site Updated

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Southampton : Research Site

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

Southampton : Department of Medical Oncology, Southampton General Hospital

Study of a DNA Immunotherapy to Treat Melanoma

Sutton : GSK Investigational Site Updated

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Sutton : Novartis Investigative Site

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Sutton :

A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Swansea : GSK Investigational Site Updated

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Truro : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Truro :

A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma

Truro, Cornwall : Local Institution

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Wirral : Updated

A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Wirral : Clatterbridge Centre for Oncology NHS Foundation Trust

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma